DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Baselga J, Im SA, Iwata H. et al.
PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE‑2 trial. San Antonio Breast Cancer Symposium.
San Antonio, TX, USA: ; Abstract S6-01 2015
Access:
We do not assume any responsibility for the contents of the web pages of other providers.